Using RNA technology to improve heart cell regeneration after heart attacks
Engineering RNA biodevices for precise modulation of fibroblasts to boost cardiac reprogramming
['FUNDING_R21'] · UNIVERSITY OF CINCINNATI · NIH-11036913
This study is exploring a new way to help heal the heart after a heart attack by using special tools to turn certain cells into healthy heart cells, making it easier and safer to treat heart damage without surgery.
Quick facts
| Phase | ['FUNDING_R21'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF CINCINNATI (nih funded) |
| Locations | 1 site (CINCINNATI, UNITED STATES) |
| Trial ID | NIH-11036913 on ClinicalTrials.gov |
What this research studies
This research focuses on developing innovative RNA biodevices that can precisely modulate fibroblasts, which are cells that can contribute to heart damage after a heart attack. By using advanced techniques like CRISPR, the goal is to convert these fibroblasts into functional heart cells, promoting heart regeneration. The approach aims to deliver genes directly to the fibroblasts in the heart, avoiding the need for invasive procedures. The research also addresses challenges in ensuring that the treatment specifically targets fibroblasts without affecting other heart cells.
Who could benefit from this research
Good fit: Ideal candidates for this research would be individuals who have experienced a myocardial infarction and are at risk of heart failure due to excessive fibrosis.
Not a fit: Patients who have not had a heart attack or do not have significant fibrosis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that regenerate heart tissue and improve recovery after heart attacks.
How similar studies have performed: While the approach of using RNA technology for cardiac reprogramming is promising, it is still largely novel and untested in clinical settings.
Where this research is happening
CINCINNATI, UNITED STATES
- UNIVERSITY OF CINCINNATI — CINCINNATI, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: LIANG, JIALIANG — UNIVERSITY OF CINCINNATI
- Study coordinator: LIANG, JIALIANG
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.